| Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections (NCT04793100) | Fondation Ophtalmologique Adolphe de Rothschild | 2021-03-24 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (NCT04740931) | Hoffmann-La Roche | 2021-03-02 |
| 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) (NCT04667910) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-01-27 |
| Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. (NCT04601701) | He Eye Hospital | 2020-10-17 |
| Treatment of Central Retinal Vein Occlusion Using Stem Cells Study (NCT03981549) | The Emmes Company, LLC | 2019-10-22 |
| Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (NCT03810313) | Novartis Pharmaceuticals | 2019-07-03 |
| Surgical Stabilizer Assisted RVC With rtPA for CRVO (NCT03417401) | Universitaire Ziekenhuizen KU Leuven | 2018-10-16 |
| Phase I RVC With Ocriplasmin for CRVO (NCT02747030) | Universitaire Ziekenhuizen KU Leuven | 2016-12-01 |
| Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO (NCT02800642) | Bayer | 2016-06-10 |
| Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion (NCT03223714) | Chengdu Kanghong Biotech Co., Ltd. | 2016-05-24 |
| Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO (NCT02503540) | Justis Ehlers | 2015-08-18 |
| Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients (NCT02405741) | Assaf-Harofeh Medical Center | 2015-03-01 |
| Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen (NCT02274259) | Anders Kvanta | 2014-10-01 |
| Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) (NCT01969708) | The Emmes Company, LLC | 2014-09-01 |
| Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study (NCT02390245) | Wills Eye | 2014-09-01 |
| Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I (NCT02173873) | Rafic Hariri University Hospital | 2014-06-01 |
| Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO (NCT02091505) | Mie University | 2013-12-01 |
| Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion (NCT02169648) | Tokyo Medical University | 2013-12-01 |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (NCT01976312) | Novartis Pharmaceuticals | 2013-11-12 |
| Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion (NCT01827722) | Valley Retina Institute | 2013-05-01 |
| Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study (NCT01793181) | St. Erik Eye Hospital | 2013-01-01 |
| Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion (NCT01724554) | Ophthalmic Consultants of Boston | 2012-11-01 |
| Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival (NCT01640171) | Retina Vitreous Associates of Florida | 2012-07-01 |
| Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye (NCT01348633) | University of Toronto | 2012-03-01 |
| Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (NCT01535261) | Novartis Pharmaceuticals | 2012-02-01 |
| Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion (NCT01581411) | Weill Medical College of Cornell University | 2012-01-01 |
| Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (NCT01471691) | Hanscom, Thomas, M.D. | 2011-11-01 |
| Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (NCT01396083) | Novartis Pharmaceuticals | 2011-08-01 |
| A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye (NCT01531842) | Mid Atlantic Retina | 2011-08-01 |
| Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO) (NCT01303276) | University of Toronto | 2011-06-01 |
| Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab (NCT01360385) | Glostrup University Hospital, Copenhagen | 2010-10-01 |
| Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) (NCT01231633) | Long Island Vitreoretinal Consultants | 2010-09-01 |
| Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion (NCT01028248) | California Retina Consultants | 2010-01-01 |
| Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO) (NCT01178697) | Shahid Beheshti University of Medical Sciences | 2010-01-01 |
| Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion (NCT01448018) | Centre Hospitalier Intercommunal Creteil | 2010-01-01 |
| Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion (NCT01011374) | Retina Associates of Cleveland, Inc | 2009-11-01 |
| Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion (NCT00969293) | Fovea Pharmaceuticals SA | 2009-09-01 |
| Bevacizumab for Central Retinal Vein Occlusion Study (NCT00906685) | Anders Kvanta | 2009-05-01 |
| Atorvastatin for the Treatment of Retinal Vein Occlusion (NCT00517257) | University of Toronto | 2007-08-01 |
| A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO (NCT00567697) | Aleris Helse | 2007-03-01 |
| Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions (NCT00500045) | Palo Alto Medical Foundation | 2007-02-01 |
| A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging (NCT00556114) | University of California, Irvine | 2007-01-01 |
| Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion (NCT00383773) | Hadassah Medical Organization | 2006-10-01 |
| The Effectiveness of Intravitreal Avastin Injection for CRVO (NCT01678248) | Ziv Hospital | 2006-01-01 |
| Lucentis for Central Retinal Vein Occlusion (CRVO) (NCT00406796) | California Retina Consultants | 2006-01-01 |
| The ROVO Study: Radial Optic Neurotomy for CVO (NCT00532142) | Rudolf Foundation Clinic | 2005-04-01 |
| A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion (NCT00952614) | Glenn Jaffe | 2002-10-01 |
| Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). (NCT00211471) | Manhattan Eye, Ear & Throat Hospital | 2002-03-01 |